XML 68 R36.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration and Licensing Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration and Licensing Revenues | The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2020, 2019 and 2018.
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018
ZIOPHARM Oncology, Inc. | $ | 200 |  |  | $ | 2,171 |  |  | $ | 16,298 |
Ares Trading S.A. | — |  |  | — |  |  | 11,175 |
Oragenics, Inc. | 3,053 |  |  | (564) |  |  | 1,353 |
Intrexon T1D Partners, LLC | — |  |  | — |  |  | 2,502 |
Intrexon Energy Partners, LLC | — |  |  | 2,596 |  |  | 6,929 |
Intrexon Energy Partners II, LLC | — |  |  | 1,217 |  |  | 2,998 |
Castle Creek Biosciences, Inc. | 17,810 |  |  | 3,713 |  |  | 1,394 |
Harvest start-up entities (1) | — |  |  | 4,862 |  |  | 14,447 |
Other | 145 |  |  | 64 |  |  | 12,444 |
Total (2) | $ | 21,208 |  |  | $ | 14,059 |  |  | $ | 69,540 |
(1)For the years ended December 31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December 31, 2018, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics and CRS Bio. (2)Collaboration and licensing revenues recognized for the years ended December 31, 2020, 2019 and 2018, include the recognition of $20,205, $7,505, and $39,446, respectively, associated with upfront and milestone payments which were previously deferred.
Summary of Deferred Revenue | Deferred revenue consisted of the following:
| December 31,
| 2020 |  | 2019
Collaboration and licensing agreements | $ | 23,420 |  |  | $ | 50,593 |
Prepaid product and service revenues | 2,126 |  |  | 2,805 |
Other | 277 |  |  | 435 |
Total | $ | 25,823 |  |  | $ | 53,833 |
Current portion of deferred revenue | $ | 2,800 |  |  | $ | 5,697 |
Long-term portion of deferred revenue | 23,023 |  |  | 48,136 |
Total | $ | 25,823 |  |  | $ | 53,833 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December 31, 2020 and 2019, as well as the estimated remaining performance period as of December 31, 2020.
| Average Remaining Performance Period (Years) |  | December 31,
|  | 2020 |  | 2019
Oragenics, Inc. | 0.0 |  | $ | — |  |  | $ | 2,864 |
Intrexon Energy Partners, LLC | 3.2 |  | 8,362 |  |  | 8,362 |
Intrexon Energy Partners II, LLC | 3.9 |  | 12,843 |  |  | 12,843 |
Castle Creek Biosciences, Inc. | 1.0 |  | 379 |  |  | 17,697 |
Harvest start-up entities (1) | 0.0 |  | — |  |  | 6,993 |
Other | 2.2 |  | 1,836 |  |  | 1,834 |
Total |  |  | $ | 23,420 |  |  | $ | 50,593 |
(1)As of December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Exotech Bio, and AD Skincare.

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration